|
|
|
| Clinical Effect of Loading Dose Plus High Maintenance Dose of Atorvastatin in Treating ACS and the Influence on Serum Inflammatory Factors and Vascular Endothelial Function |
| WANG Zhu, ZHENG Weimin |
| Hainan Western Central Hospital, Hainan Danzhou 571700, China |
|
|
|
|
Abstract Objective: To explore the clinical curative effect of loading dose plus high maintenance dose of atorvastatin in treating acute coronary syndrome (ACS) and the influence on serum inflammatory factors and vascular endothelial function. Methods: 96 patients with ACS treated by percutaneous coronary intervention (PCI) were equally divided into the experimental group and the control group by random number method. The two groups were treated with conventional dose (20mg/d) and loading dose plus high maintenance dose (80mg/d before operation, 40mg/d after operation, 20mg/d 1 month later) of atorvastatin, respectively. Serum inflammatory factors (hs-CRP, IL-6, TNF-α), vascular endothelial function (NO, ET-1) and yocardial injury markers (CK,CK-MB) were determined before and after treatment. The incidence rates of major adverse cardiovascular events in the two groups within 3 months after discharge were statistically analyzed. Results: Levels of serum hs-CRP, IL-6, TNF-α, ET-1, CK and CK-MB in the two groups decreased significantly in 1 month after treatment, while NO levels increased significantly, compared with those before operation (before medication). The decrease or increase in the experimental group were significantly greater than those in the control group (P < 0.05). The incidence rate of major adverse cardiovascular events in the experimental group was significantly lower than that in the control group within 3 months after discharge (8.33% vs 22.92%) (P < 0.05). Conclusion: The loading dose plus high maintenance dose of atorvastatin can significantly inhibit the release of inflammatory factors, improve the endothelial function, effectively protect the myocardium of patients with ACS, and significantly reduce the incidence rate of adverse cardiovascular events.
|
|
|
|
|
|
[1] 董丽君,洪子惠.负荷量加高维持量的阿托伐他汀在ACS患者介入治疗后的临床应用效果[J].中国循证心血管医学杂志,2016,8(4):474~476,479.
[2] 李慧芳,李颖,王霞,等.不同剂量阿托伐他汀对急性冠脉综合征患者早期血浆超敏C反应蛋白水平的影响[J].中国老年学杂志,2017,37(4):855~856.
[3] 杨丽,刘寅,王树峰,等.普罗布考联合阿托伐他汀对ACS患者PCI术后ox-LDL及Lp-PLA2水平的影响[J].天津医药,2017,45(1):47~50.
[4] 中国医师协会急诊医师分会,中华医学会心血管病学分会,中华医学会检验医学分会等.急性冠脉综合征急诊快速诊疗指南[J].中华急诊医学杂志,2016,25(4):397~404.
[5] Da-Kui X U.Significance of ultrasound combining with hs-CRP in determining the diagnosis of ACS[J].Journal of Hainan Medical University,2015,21(1):137~139.
[6] 尹彬.不同剂量瑞舒伐他汀对ACS患者血清炎症因子及血管内皮功能的影响[J].河北医学,2016,22(8):1297~1299.
[7] 张亮,黄文胜,冷利华,等.阿托伐他汀负荷量加高维持量对急性冠状动脉综合征患者血管内皮功能及心功能的影响[J].中国医药,2017,12(10):1478~1482.
[8] 丁胜华,仵淑娟,郑立娇,等.不同剂量阿托伐他汀预处理对经皮冠状动脉介入治疗患者的保护作用[J].中国药房,2017,28(35):4987~4989.
[9] 黄兴红,杨永曜.负荷量阿托伐他汀对急性冠脉综合征经皮冠脉介入术治疗患者心肌灌注、炎症反应及内皮功能的影响[J].中国老年学杂志,2016,36(8):1851~1852. |
|
|
|
2018, Vol. 24 
